Sumitomo Dainippon Predicts 20-30 Billion Yen Sales from “Frontier Business” by FY2027

Sumitomo Dainippon Pharma expects that its “frontier business” could generate sales of 20-30 billion yen by FY2027 based on its current portfolio, and possibly 100 billion yen by FY2032 if potential growth in the US is factored in. The Osaka-based...read more